Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET)
CUSIP: 007002108
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.0001
- Shares outstanding
- 9,599,852
- Total 13F shares
- 51,603,071
- Share change
- -4,252,966
- Total reported value
- $31,484,026
- Put/Call ratio
- 0%
- Price per share
- $0.61
- Number of holders
- 47
- Value change
- -$3,114,221
- Number of buys
- 20
- Number of sells
- 32
Quarterly Holders Quick Answers
What is CUSIP 007002108?
CUSIP 007002108 identifies ACET - Adicet Bio, Inc. - Common Stock, par value $0.0001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 007002108:
Top shareholders of ACET - Adicet Bio, Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
|
Company |
119%
|
11,447,140
|
$8,642,591 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Company |
9.9%
|
8,223,612
|
$6,208,827 | $0 | 31 Mar 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
79%
|
7,541,000
|
$5,693,455 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
40%
|
3,816,556
|
$2,881,500 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
33%
|
3,205,882
|
$2,420,441 | — | 31 Mar 2025 | |
| Carlyle Group Inc. |
13F
|
Company |
31%
|
2,948,718
|
$2,276,705 | — | 31 Mar 2025 | |
| Aquilo Capital Management, LLC |
13F
|
Company |
26%
|
2,456,194
|
$1,854,426 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
21%
|
2,039,324
|
$1,538,000 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
13%
|
1,248,711
|
$942,777 | — | 31 Mar 2025 | |
| Carl L. Gordon |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
684,857
mixed-class rows
|
$941,594 | — | 21 Aug 2024 | |
| Blackstone Inc. |
13F
|
Company |
13%
|
1,236,453
|
$933,522 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
13%
|
1,223,869
|
$924,021 | — | 31 Mar 2025 | |
| REGENERON PHARMACEUTICALS, INC. |
13F
|
Company |
10%
|
968,183
|
$730,978 | — | 31 Mar 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
9.4%
|
901,600
|
$680,708 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
8.4%
|
810,700
|
$612,079 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
8%
|
770,703
|
$582,056 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
7.8%
|
749,067
|
$565,546 | — | 31 Mar 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
6.8%
|
655,665
|
$495,027 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
6.5%
|
622,839
|
$470,243 | — | 31 Mar 2025 | |
| RBF Capital, LLC |
13F
|
Company |
6.4%
|
617,319
|
$466,076 | — | 31 Mar 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
6.3%
|
600,000
|
$453,000 | — | 31 Mar 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
5.3%
|
505,469
|
$381,629 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
5.2%
|
494,978
|
$373,708 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
4.8%
|
457,722
|
$345,580 | — | 31 Mar 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
3.8%
|
364,472
|
$275,176 | — | 31 Mar 2025 | |
| Francesco Galimi |
3/4/5
|
SVP & Chief Medical Officer |
—
mixed-class rows
|
476,878
mixed-class rows
|
$244,322 | — | 05 Jun 2024 | |
| Aya Jakobovits |
3/4/5
|
Director |
—
mixed-class rows
|
176,276
mixed-class rows
|
$214,323 | — | 21 Aug 2024 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
5.3%
|
508,266
|
$203,500 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
2.6%
|
248,990
|
$187,988 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.6%
|
246,921
|
$186,425 | — | 31 Mar 2025 | |
| WEALTHEDGE INVESTMENT ADVISORS, LLC |
13F
|
Company |
2.4%
|
227,801
|
$171,990 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.5%
|
147,814
|
$111,759 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.5%
|
140,373
|
$105,982 | — | 31 Mar 2025 | |
| Lloyd Klickstein |
3/4/5
|
Director |
—
mixed-class rows
|
134,966
mixed-class rows
|
$66,225 | — | 11 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.67%
|
64,039
|
$48,349 | — | 31 Mar 2025 | |
| Vontobel Holding Ltd. |
13F
|
Company |
0.63%
|
60,000
|
$46,585 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.56%
|
53,834
|
$40,645 | — | 31 Mar 2025 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.36%
|
34,247
|
$25,856 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.31%
|
30,000
|
$22,650 | — | 31 Mar 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.25%
|
23,727
|
$18,000 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.21%
|
20,541
|
$15,508 | — | 31 Mar 2025 | |
| Steve Dubin |
3/4/5
|
Director |
—
mixed-class rows
|
49,100
mixed-class rows
|
$13,847 | — | 11 Jun 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.19%
|
18,288
|
$13,807 | — | 31 Mar 2025 | |
| CAXTON CORP |
13F
|
Company |
0.18%
|
17,488
|
$13,203 | — | 31 Mar 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.17%
|
16,299
|
$12,306 | — | 31 Mar 2025 | |
| Ground Swell Capital, LLC |
13F
|
Company |
0.17%
|
15,947
|
$12,040 | — | 31 Mar 2025 | |
| Andrew Sinclair |
3/4/5
|
Director |
—
mixed-class rows
|
44,100
mixed-class rows
|
$10,797 | — | 11 Jun 2025 | |
| Jeffrey Chodakewitz |
3/4/5
|
Director |
—
mixed-class rows
|
44,100
mixed-class rows
|
$10,797 | — | 11 Jun 2025 | |
| Point72 Asia (Singapore) Pte. Ltd. |
13F
|
Company |
0.14%
|
13,473
|
$10,172 | — | 31 Mar 2025 | |
| StoneX Group Inc. |
13F
|
Company |
0.13%
|
12,448
|
$9,398 | — | 31 Mar 2025 |
Institutional Holders of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) as of Q2 2025
As of 30 Jun 2025,
Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) was held by
47 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
51,603,071 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, TANG CAPITAL MANAGEMENT LLC, RA CAPITAL MANAGEMENT, L.P., GOLDMAN SACHS GROUP INC, VANGUARD GROUP INC, Carlyle Group Inc., ACADIAN ASSET MANAGEMENT LLC, Schonfeld Strategic Advisors LLC, RENAISSANCE TECHNOLOGIES LLC, and REGENERON PHARMACEUTICALS, INC..
This page lists
47
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
56
Q2 2025 holders
47
Holder diff
-9
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.